| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/23/2002 | EP1173223A2 Conjugates as therapies for cancers and prostate diseases |
| 01/23/2002 | EP1173220A2 Targeting of infectious agents bearing host cell proteins |
| 01/23/2002 | EP1173217A2 Enhanced delivery of nucleic acid-based drugs |
| 01/23/2002 | EP1173213A1 Compositions containing benzimidazolones and progestogens |
| 01/23/2002 | EP1173212A1 Contraceptive compositions contaning indolone derivatives and progestational agents |
| 01/23/2002 | EP1173211A1 Contraceptive compositions containing 3,3-substituted indoline derivatives and uses thereof |
| 01/23/2002 | EP1173210A1 Contraceptive compositions containing antiprogestinic and progestinic |
| 01/23/2002 | EP1173209A1 Contraceptive compositions containing 2,1-benzisothiazoline 2,2-dioxides and progestationals |
| 01/23/2002 | EP1173208A2 Contraceptive compositions containing cyclic urea and amide derivatives |
| 01/23/2002 | EP1173207A2 Miotic agents and hypertonic agents containing ophthalmic compositions |
| 01/23/2002 | EP1173206A1 Contraceptive compositions containing quinazolinone and benzoxazine derivatives |
| 01/23/2002 | EP1173205A1 An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
| 01/23/2002 | EP1173202A1 Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
| 01/23/2002 | EP1173197A2 Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue |
| 01/23/2002 | EP1173196A1 New use of a substance in pns |
| 01/23/2002 | EP1173192A2 Methods and compositions for targeted drug delivery |
| 01/23/2002 | EP1173187A2 Combined preparations comprising morpholine anthracyclines and anticancer agent |
| 01/23/2002 | EP1173186A1 Use of tagatose to enhance key blood factors |
| 01/23/2002 | EP1173183A2 Use of compounds with a nitrogen-oxygen heterocycle |
| 01/23/2002 | EP1173181A2 Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction |
| 01/23/2002 | EP1173174A1 Methods for treatment of sickle cell anemia |
| 01/23/2002 | EP1173168A2 Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| 01/23/2002 | EP1173164A2 Estrogen receptor-beta ligands |
| 01/23/2002 | EP1173161A2 Glucamine compounds for treating hepatitis virus infections |
| 01/23/2002 | EP1173155A1 Gum pad for delivery of medication to mucosal tissues |
| 01/23/2002 | EP1173152A2 Solid pharmaceutical formulations of acid-sensitive proton-pump blockers |
| 01/23/2002 | EP1173147A2 Sunscreen agents containing hydroxycarboxylic acid alkyl,-and/or alkenyloligo- glycoside esters |
| 01/23/2002 | EP1173145A1 Composition for cosmetic and dermatological skin care |
| 01/23/2002 | EP1173061A1 Compositions and methods for treatment of hyperproliferative diseases |
| 01/23/2002 | EP0980254B1 Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity |
| 01/23/2002 | EP0854711B1 gamma-RAR ANTAGONIST LIGAND OR alpha-RAR AGONIST LIGAND AS AN APOPTOSIS INHIBITOR |
| 01/23/2002 | CN1332849A Methods and compositions to lower plasma cholesterol levels |
| 01/23/2002 | CN1332799A Cancer cell vaccine |
| 01/23/2002 | CN1332748A Isolated nucleic acid molecules which encodt T cell inducible factors (TIFs), proteins encoded, and uses thereof |
| 01/23/2002 | CN1332745A New compounds for treatment of cancer |
| 01/23/2002 | CN1332740A 5HT antagonists for antidepressant therapy |
| 01/23/2002 | CN1332638A Combination comprising beta-agonist and further antidiabetic agent |
| 01/23/2002 | CN1332628A Method of treating sexual disturbances |
| 01/23/2002 | CN1332626A Inhalation system |
| 01/23/2002 | CN1332167A Eprosartan dihydrate and its prep. |
| 01/23/2002 | CN1078074C Composition for treating and inhibiting gastric and duodenal ulcers |
| 01/23/2002 | CN1078072C Use of 1 alpha, 24-dihydroxy vitamin D2 |
| 01/23/2002 | CN1078071C Use of pharmaceutical compositions |
| 01/22/2002 | US6340709 Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
| 01/22/2002 | US6340696 Administering therapeutically effective amount of combination of (5-aryl-1,2,4-thiadiazol)-3-yl thiourea derivative or (5-aryl-1,2,4-thiadiazol)-3-yl urea derivative and ribavirin and/or interferon |
| 01/22/2002 | US6340688 Administering to female during menstrual cycle amount of competitive progesterone antagonist which is less than ovulation-inhibiting dose and less than abortion-inductive dose |
| 01/22/2002 | US6340681 Useful as analgesics in mammals |
| 01/22/2002 | US6340575 An isolated nucleic acid encoding a ras superfamily, rac gene, that modulates gtpase activity; cancer therapy |
| 01/22/2002 | US6340476 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 01/22/2002 | US6340463 For the production of both polyclonal and monoclonal antibodies to defined antigenic domains |
| 01/22/2002 | US6340459 Administering to agent capable of inhibiting interaction between cd40 ligand and the cells to inhibit activation of the cells in therapy of reperfusion injury, in an non-transplant recipient |
| 01/22/2002 | CA2259962C Therapeutic applications of t-bam (cd40l) technology to treat diseases involving smooth muscle cells |
| 01/22/2002 | CA2121435C Aqueous pharmaceutical suspension and process for preparation thereof |
| 01/17/2002 | WO2002004952A2 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 01/17/2002 | WO2002004949A2 Reagents and methods for identification of binding agents |
| 01/17/2002 | WO2002004946A2 Methods for identifying combinations of drugs |
| 01/17/2002 | WO2002004623A2 ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE |
| 01/17/2002 | WO2002004612A2 Drug metabolizing enzymes |
| 01/17/2002 | WO2002004611A2 Aminoacyl trna synthetases |
| 01/17/2002 | WO2002004606A1 Use of bioactive glass compositions to stimulate osteoblast production |
| 01/17/2002 | WO2002004605A2 Stimulation of cellular regeneration and differentiation in the inner ear |
| 01/17/2002 | WO2002004520A2 Transporters and ion channels |
| 01/17/2002 | WO2002004514A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/17/2002 | WO2002004513A2 Down syndrome critical region 1-like 1 proteins |
| 01/17/2002 | WO2002004499A1 Chemokine receptor modulators, production and use |
| 01/17/2002 | WO2002004491A2 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) |
| 01/17/2002 | WO2002004490A2 Lipid metabolism molecules |
| 01/17/2002 | WO2002004482A1 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 01/17/2002 | WO2002004440A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
| 01/17/2002 | WO2002004421A2 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 01/17/2002 | WO2002004420A1 Piperidine coumpounds for use as ccr-3 inhibitors |
| 01/17/2002 | WO2002004418A2 Methods of inhibiting uterotrophic effects of estrogenic agents |
| 01/17/2002 | WO2002004031A1 Compositions and methods for treating cardiovascular disorders |
| 01/17/2002 | WO2002004029A1 Olfactory neuron cultures and method of making and using the same |
| 01/17/2002 | WO2002004024A1 Composition for the treatment of diabetes |
| 01/17/2002 | WO2002004021A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/17/2002 | WO2002004015A1 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/17/2002 | WO2002004003A2 Composition for the treatment of osteoarthritis |
| 01/17/2002 | WO2002003996A1 Use of dammarane-type tritepenoid saporins |
| 01/17/2002 | WO2002003995A2 Treatment of male sexual dysfunction |
| 01/17/2002 | WO2002003979A2 Combination of 2-methoxyestradiol and an agent that increases intracellular superoxide anion |
| 01/17/2002 | WO2002003978A2 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES |
| 01/17/2002 | WO2002003977A2 Combinations of statins, estrogenic agents and optionally estrogens |
| 01/17/2002 | WO2002003976A2 Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
| 01/17/2002 | WO2002003975A2 Combinations of ssri and estrogenic agents |
| 01/17/2002 | WO2002003971A2 Pharmaceutical composition and method for the treatment of retroviral infections |
| 01/17/2002 | WO2002003945A1 Use of oligosaccharides to stimulate beta-endorphin production |
| 01/17/2002 | WO2002003911A2 Prevention and treatment of alzheimer's disease |
| 01/17/2002 | WO2002003886A1 Treatment of human herpesviruses using hyperthermia |
| 01/17/2002 | WO2002003815A2 Composition for the treatment of migraine |
| 01/17/2002 | WO2001072962A3 Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/17/2002 | WO2001064200A3 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| 01/17/2002 | WO2001054681A8 Composition for treatment of stress |
| 01/17/2002 | WO2001054678A3 Combination therapy for cancer |
| 01/17/2002 | WO2001049838A3 Cis-acting regulatory nucleic acid sequences in the parathyroid hormone 3'-untranslated region |
| 01/17/2002 | WO2001047950A3 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 01/17/2002 | WO2001047543A3 Activation and inhibition of the immune system |
| 01/17/2002 | WO2001044448A3 Human oxidoreductase proteins |
| 01/17/2002 | WO2001044291A3 Polynucleotid encoding the rg1 polypeptide |
| 01/17/2002 | WO2001039759A3 Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |